{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
levacetylleucine
to a specific field?
There is one exact (name or code) match for levacetylleucine
Status:
US Approved Rx
(2024)
Source:
NDA219132
(2024)
Source URL:
First approved in 2020
Source:
BACICAP PROBIOTIC by NATIONAL BIO GREEN SCIENCES LIMITED LIABILTY COMPANY
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
L-Acetylleucine is enantiomer of Acetylleucine that used in the treatment of vertigo and cerebellar ataxia. The N-acetyl-L-leucine isomer is the active part of the racemate component since it induces a significant acceleration of the vestibular compensation process similar and even better than that observed under treatment with the racemate component only. Acetylleucine was aggressively marketed in France for vertigo. It may act as a precursor of a peptidic neuromediator responsible for activation of vestibular afferents. It may also have ‘anticalcium’ properties on neurotransmission. Pierre Fabre conducted clinical studies of L-Acetoleusine for Vertigo and Dizzinesstherapy. However, all clinical studies were discontinued
Showing 1 - 5 of 5 results
Status:
US Approved Rx
(2024)
Source:
NDA219132
(2024)
Source URL:
First approved in 2020
Source:
BACICAP PROBIOTIC by NATIONAL BIO GREEN SCIENCES LIMITED LIABILTY COMPANY
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
L-Acetylleucine is enantiomer of Acetylleucine that used in the treatment of vertigo and cerebellar ataxia. The N-acetyl-L-leucine isomer is the active part of the racemate component since it induces a significant acceleration of the vestibular compensation process similar and even better than that observed under treatment with the racemate component only. Acetylleucine was aggressively marketed in France for vertigo. It may act as a precursor of a peptidic neuromediator responsible for activation of vestibular afferents. It may also have ‘anticalcium’ properties on neurotransmission. Pierre Fabre conducted clinical studies of L-Acetoleusine for Vertigo and Dizzinesstherapy. However, all clinical studies were discontinued
Status:
Designated
Source:
FDA ORPHAN DRUG:381712
Source URL:
Class:
PROTEIN
